Omnicell (NASDAQ:OMCL) Earns Buy Rating from Benchmark

Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating restated by equities research analysts at Benchmark in a research report issued on Tuesday,Benzinga reports. They currently have a $62.00 target price on the stock. Benchmark’s price target indicates a potential upside of 39.70% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company cut their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Craig Hallum upped their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Bank of America cut their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $52.33.

Omnicell Stock Performance

Shares of Omnicell stock opened at $44.38 on Tuesday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The company has a fifty day moving average of $44.60 and a 200 day moving average of $43.22. The company has a market capitalization of $2.06 billion, a P/E ratio of -113.79, a P/E/G ratio of 30.78 and a beta of 0.78.

Insider Activity

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.64% of the company’s stock.

Institutional Trading of Omnicell

Large investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its stake in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after buying an additional 273 shares during the period. Van ECK Associates Corp lifted its position in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the period. GAMMA Investing LLC boosted its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the period. Finally, KBC Group NV raised its stake in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.